Jamjoom Pharmaceuticals Factory (4015)
Tadawul
138.90
-2.10 (-1.49%)
Closed
Aug 27, 2026
Day's Range
138.90142.40
52 wk Range
125.00165.30
Financial Statements - 4015 - Jamjoom Pharmaceuticals Factory
Revenue
1.50B▲ 13.8%
Net Income
463.80M▲ 30.1%Net Margin 30.9%
EBITDA
540.25M▲ 22.0%
Free Cash Flow
331.97M▲ 60.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 1.50B | 1.31B | 1.10B | 916.67M | 735.68M | 805.31M |
| Cost of Goods | 561.82M | 497.97M | 397.03M | 322.74M | 260.98M | 292.01M |
| Gross Profit | 938.80M | 820.50M | 703.78M | 593.92M | 474.69M | 513.29M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 477.53M | 399.20M | 316.47M | 243.30M | 186.55M | 239.91M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 493.09M | 382.65M | 315.79M | 186.31M | 188.08M | 231.74M |
| Income Tax | 29.29M | 26.12M | 23.39M | 15M | 17.39M | 24.88M |
| Net Income | 463.80M | 356.52M | 292.40M | 171.31M | 170.69M | 206.86M |
| EPS Basic | 6.63 | 5.09 | 4.18 | 2.447345 | 2.438504 | 2.955147 |
| EPS Diluted | 6.63 | 5.09 | 4.18 | 2.447345 | 2.438504 | 2.955147 |
| Basic Shares Outstanding | 70M | 70M | 70M | 70M | 70M | 70M |
| Diluted Shares Outstanding | 70M | 70M | 70M | 70M | 70M | 70M |
| Ebit | 493.29M | 382.75M | 315.91M | 186.43M | 188.19M | 239.91M |
| Ebitda | 540.25M | 442.81M | 348.35M | 223.85M | 216.77M | 290.36M |
| Net Income Continuous Operations | 493.09M | 382.65M | 315.79M | 186.31M | 188.08M | 231.74M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
